What platforms support n-of-1 therapy design or personalized medicine workflows?

The landscape of N-of-1 trial design (personalized, single-patient, multi-crossover randomized trials) and individualized medicine workflows has evolved significantly through open-source software and digital health platforms.

Key platforms and digital toolsets supporting N-of-1 designs and personalized medicine workflows include:

• StudyU Platform: An open-source digital platform built explicitly to design, publish, and run N-of-1 trials. It is split into StudyU Designer (a collaborative web application for researchers and clinicians to specify trial protocols, interventions, and randomizations) and the StudyU App (a mobile/web application for participants to track interventions, receive daily reminders, and view real-time feedback or analytics).
• N-of-1 Hub: A specialized consultancy and collaboration network working with researchers, clinicians, and industry partners to evaluate treatments, supplements, and digital health interventions using N-of-1 and Single-Case Experimental Designs (SCEDs). They assist with the rigorous protocol design, randomisation, blinding, and statistical analysis (such as Bayesian modeling) required for individual clinical utility.
• N of 1 Health Research Platform (Digital Infuzion): A SaaS enterprise platform designed for patient-centric longitudinal research, rare diseases, and real-world evidence generation. It integrates Electronic Data Capture (EDC), Electronic Medical Records (EMR), and electronic Patient-Reported Outcomes (ePRO) to track individual trajectories and aggregate real-world data at the patient level.
• Trial-Ready Registries & International Collaborative Network (ICN) Tools: Open-source and registry-based infrastructures developed to support adaptive and N-of-1 trials. These systems enable the seamless capture and linking of patient-reported data with clinical health system data, often embedding real-time Bayesian analytical frameworks to calculate individualized treatment effects.
• Statistical Environments (Stats-of-1 & R Packages): For custom analytical workflows, resources like Stats-of-1 offer educational guides, computational tools, and methodologies tailored to analyzing single-case and N-of-1 trial data using advanced frequentist and Bayesian approaches.

Would you like to explore how to set up a trial protocol in StudyU , or are you looking for guidance on the Bayesian statistical methods used to analyze N-of-1 data?

Yes. There are a few different categories, and it helps to distinguish true N-of-1 trial platforms from broader precision/personalized-medicine platforms.

Platforms specifically suited to N-of-1 designs

StudyU is probably the closest match if you mean a platform where a researcher/clinician can actually define, deploy, and analyze individualized N-of-1 experiments. It has a web-based StudyU Designer plus a participant smartphone app, supports customizable interventions/outcomes, and is open source/self-hostable.

The research literature also identifies PACO, movisensXS, OpenClinica, Trialist, QuantifyMe, TummyTrials, and SleepCoacher as platforms/apps that have supported individual-level studies, although several have important limitations around customization or statistical analysis.

Broader personalized-medicine workflows

If by "personalized medicine" you mean matching a patient's characteristics to treatments, rather than running repeated treatment experiments within the same patient, the ecosystem is much larger. Typical platforms fall into:

• Clinical genomics / molecular profiling — genomic interpretation, variant analysis, tumor profiling and treatment matching.
• Clinical decision support — combining patient-specific clinical data with guidelines, biomarkers, and predictive models.
• Real-world evidence platforms — longitudinal EHR, claims, wearable, and patient-reported data used to estimate individual treatment response.
• Precision oncology platforms — molecularly characterize a tumor and identify potentially relevant therapies or trials.
• Digital therapeutics / remote monitoring — continuously collect patient-level outcomes and adapt interventions.

These aren't necessarily N-of-1 systems. In fact, conventional precision-medicine platforms often predict which treatment should work for an individual, whereas an N-of-1 platform experimentally tests alternatives within that individual. That's an important distinction.

If you're evaluating platforms for a real workflow

I'd look for these capabilities:

1. Treatment randomization — AB, ABA/BAB, ABAB, crossover, blocked, etc.
2. Adaptive designs — ability to change treatment allocation based on accumulating individual-level evidence.
3. Washout/carryover modeling — particularly important for medications.
4. High-frequency outcome collection — PROs, sensors, wearables, biomarkers.
5. Longitudinal patient data integration — EHR/FHIR, Apple Health, wearables, labs.
6. Individual-level statistics — treatment effect, uncertainty, Bayesian updating, sequential analysis.
7. Patient-facing results — not merely collecting data but explaining what appears to work for that individual.
8. Clinician/researcher workflow — protocol authoring, consent, monitoring, audit trails and exports.
9. Self-hosting/data governance — important if the platform will handle PHI.
10. Multi-patient aggregation — ability to combine many N-of-1 trials into population-level evidence.

A particularly interesting direction is adaptive N-of-1 experimentation. Recent work has proposed "Platform-of-1" designs that adaptively allocate multiple candidate treatments to an individual rather than simply alternating two treatments.

Bottom line: if you're specifically looking for a platform to build an individualized treatment-testing workflow, I'd put StudyU at the top of the shortlist today. If you're building a more comprehensive precision-medicine system, you'd probably combine an N-of-1 experimentation layer with EHR/FHIR, genomics, wearable/PRO data, and a clinical decision-support layer rather than expect one product to do everything.

If you tell me whether you're looking for (a) clinical use, (b) research trials, (c) a startup/product stack, or (d) patient self-experimentation, I can give you a much more concrete comparison of ~10 platforms, including APIs, pricing/licensing, FHIR/EHR integration, statistical methods, and whether they're actually usable in 2026.

The landscape for n-of-1 therapy design and personalized/single-case experimental medicine workflows has evolved through open-source software, digital health applications, and specialized contract research infrastructure . Unlike traditional population-average trials, these platforms focus on intra-individual responses using randomized, multi-crossover or sequential tracking.

Key Platforms and Tools Supporting n-of-1 Workflows

1. StudyU Platform (n-of-1 Open Source Framework)
   • What it is: A comprehensive, open-source digital platform explicitly built for creating and executing digital n-of-1 trials. It is split into two components:
     • StudyU Designer: A collaborative web app enabling clinicians, researchers, and health innovators to specify, configure, and publish n-of-1 trial parameters, intervention schedules, and randomizations.
     • StudyU App: A mobile companion app (available on iOS and Android) where participants track symptoms, receive timed intervention cues, and visualize their personal treatment responses.
   • Best for: Academic researchers, clinicians, and digital health developers wanting a customizable, open-source infrastructure. You can explore the tool via the StudyU Web Application.
2. N-of-1 Hub
   • What it is: An organization and collaborative network that works with pharmaceutical, medical technology, digital health, and academic partners to deploy n-of-1 and single-case experimental designs (SCEDs). They bridge the gap between commercial product evaluation and personalized response measurement.
   • Best for: Translational researchers, life science companies, and clinical teams looking for consulting, operational architecture, and trial execution using rigorous n-of-1 frameworks. More details are available at the N-of-1 Hub.
3. StudyMe App
   • What it is: An offshoot user-centric mobile application designed to push n-of-1 capabilities directly into the hands of individual consumers or patients. Unlike platforms gated strictly behind a clinical researcher's dashboard, StudyMe is tailored to give individuals autonomous control to structure self-tracking experiments and evaluate personal interventions.
   • Best for: Self-experimentation, quantified-self tracking, and patient-led optimization.
4. QuantifyMe
   • What it is: A mobile-accessible framework that hosts structured, fixed-schedule single-subject trials created by administrative researchers. It handles participant scheduling and data collection for individual tracking studies.
   • Best for: Mobile micro-trials and structured behavioral or lifestyle interventions.
5. International Collaborative Network (ICN) Trial-Ready Registries
   • What it is: Emerging open-source digital infrastructure supported by international networks to link patient-reported data, clinician inputs, and real-time Bayesian analytical pipelines optimized for adaptive and n-of-1 protocols.
   • Best for: Health systems and clinical networks scaling institutional single-case designs.

Are you looking to design a clinical research study for a cohort of patients, or are you trying to set up a self-tracking or consumer health workflow for personal use? Let me know, and I can narrow down the technical requirements or implementation steps.

Yes—but the market is still fragmented. There are two fairly distinct categories: platforms explicitly built for N-of-1/single-case trials, and broader precision-medicine platforms that personalize treatment using genomic, clinical, or longitudinal data.

The standout for actual N-of-1 experimentation

StudyU is probably the closest match if by "N-of-1 therapy design" you mean:

Define competing interventions → randomize/crossover periods → collect repeated patient outcomes → estimate the individual's treatment effect → feed the result back into the patient's treatment decision. Its architecture explicitly supports designing and conducting individualized trials rather than merely tracking symptoms. The platform includes a researcher-facing Designer and participant-facing app, with individual-level statistical analysis and reporting.

Recent literature continues to describe StudyU as a platform for fully digital N-of-1 trials, including integration of wearables and high-frequency measurements.

If you mean a broader "personalized medicine workflow"

That's a somewhat different stack. A mature workflow typically looks like:

patient data → phenotype/genomics → candidate interventions → individualized treatment decision → longitudinal monitoring → response assessment → treatment adjustment

Platforms such as PrecisionRx AI are targeting this clinical-decision-support layer rather than simply providing an N-of-1 trial engine. Its stated inputs include genomic, lab, medication, and wearable data, with integration into EHR environments via SMART-on-FHIR.

An important distinction

A lot of products called "personalized medicine" aren't actually N-of-1 platforms.

An N-of-1 trial has an experimental structure: the individual is repeatedly exposed to different treatment conditions, often with randomization, crossover, washout, and predefined outcomes. The purpose is to estimate that person's causal treatment effect.

By contrast, a pharmacogenomics/CDS platform might say:

"Given this patient's CYP2C19 genotype, medications, labs, and history, drug X is preferable." That's personalized medicine, but not an N-of-1 experiment.

If you're evaluating this space from a product/platform-building perspective, the interesting gap is actually the combination of the two: an N-of-1 experimentation engine + precision-medicine decision layer + EHR/wearable data integration + longitudinal treatment optimization. There don't appear to be many mature commercial systems that provide that whole loop end-to-end.

The landscape for N-of-1 trials (single-case experimental designs applied to individual medical or behavioral interventions) and personalized medicine workflows has evolved from bespoke academic research into dedicated digital health platforms.

The primary platforms and software ecosystems supporting N-of-1 and precision dosing workflows are organized below:

• StudyU — Developed as an open-source, collaborative platform specifically for digital N-of-1 trials. It consists of the StudyU Designer (a web application enabling researchers and clinicians to specify, configure, and publish randomized crossover trials) and the StudyU App (a mobile application for participants to track metrics, adhere to alternating intervention schedules, and receive individual feedback). More details are available via the StudyU Project Page.
• StudyMe — An offshoot mobile framework designed for user-centric, self-directed N-of-1 trials. Unlike StudyU, which leans toward clinician- or researcher-led protocols, StudyMe gives individuals the tools to design, execute, and analyze personalized health and behavior modification experiments directly.
• CURATE.AI — An artificial intelligence-derived clinical decision support platform that maps an individual's unique response (phenotypic output, such as blood pressure or tumor markers) against treatment intensity (such as drug dosage) using a "small-data" approach. Rather than relying on population averages, it dynamically recalibrates an individualized digital profile to provide real-time dosage titration recommendations.
• QPOP (Quadratic Phenotypic Optimization Platform) — Frequently paired with phenotypic workflows like CURATE.AI, QPOP uses individual-specific small data sets to optimize drug combinations (such as for multiple myeloma or resistant cancers) tailored to a single patient's real-time biological response.
• Digital Infuzion (N-of-1 Health Research Platform) — A enterprise-grade, real-time architecture designed to bridge patient-reported outcomes (PROs) and clinical data. It integrates electronic data capture (EDC) and electronic medical records (EMR) to support single-patient tracking and longitudinal observational studies.

If you are planning an application or research protocol, tell me:

• Are you looking for a patient-facing self-experimentation tool or a clinician-facing decision support system?
• What type of data or intervention (behavioral, pharmaceutical, dosage titration) do you need to track?

I can help you narrow down the best technical architecture or regulatory approach.

Yes. The landscape splits into true N-of-1 platforms and broader personalized/decentralized clinical-research platforms that can support N-of-1-like workflows.

The most relevant options

1. StudyU — probably the closest match to what you mean by “N-of-1 platform.”
StudyU is explicitly designed to design, run, and analyze digital N-of-1 trials. Its Designer lets researchers/clinicians specify interventions and outcomes, while the participant app conducts the study and can provide personalized treatment advice. It is open source.

2. Trialist — purpose-built N-of-1 experimentation.
The original Trialist system allowed patients and clinicians to construct personalized comparative-effectiveness studies, collect longitudinal outcomes, and generate individualized results. The original research platform was not generally available for download, but a newer Trialist app currently exists for personal Apple Health-based experiments.

3. Eureka — good if you're thinking “N-of-1 at research-program scale.”
Eureka is an NIH-sponsored mobile research platform with participant-facing apps, study management, secure data storage and analysis infrastructure. Importantly, it has actually been used for N-of-1 studies, including the I-STOP-AFib study.

4. Sano Genetics — better for precision-medicine infrastructure than N-of-1 experimentation.
Sano combines recruitment, genetic testing/biomarker workflows and longitudinal participant engagement. So it is relevant if your “personalized medicine” workflow involves genotype/phenotype → biomarker → treatment/research participation, rather than repeated randomized treatment comparisons within one person.

5. CURATE.AI — interesting for personalized dosing.
This is a different paradigm: rather than running a classic randomized AB/BA N-of-1 trial, CURATE.AI uses an individual's response data to construct a patient-specific dose–response profile and optimize therapy. It has progressed into clinical studies in areas including cancer and hypertension.

A useful distinction

If you're evaluating platforms for a product/research workflow, I'd classify them this way:

• N-of-1 trial engine: StudyU, Trialist
• Digital research/decentralized trial infrastructure: Eureka, OpenClinica, movisensXS, PACO
• Precision/genomic research workflow: Sano Genetics
• Algorithmic personalized dosing: CURATE.AI

The key capability to look for isn't simply “personalized medicine.” A genuine N-of-1 system needs some combination of within-person randomization, crossover/ABAB designs, repeated outcome measurement, intervention scheduling, adherence tracking, washout periods, and individual-level statistical analysis.

If you're assessing these because you're building or selecting a platform, I can also make a more detailed comparison of StudyU vs Eureka vs OpenClinica vs commercial DCT platforms, including API availability, randomization, EHR integration, wearables, statistical analysis, FDA/21 CFR Part 11 considerations, and pricing/licensing.

Platforms that support n-of-1 trial designs or broader personalized medicine workflows fall into several categories: dedicated n-of-1 trial tools, decentralized clinical trial (DCT) platforms, precision dosing systems, and clinical decision-support platforms.

For a true n-of-1 workflow, look for these capabilities

A platform is closer to a full n-of-1 system if it supports:

• Within-person randomization (e.g., AB, ABA, ABAB, crossover designs)
• Adaptive protocols (changing interventions based on response)
• Repeated outcome measurement
• Wearable/device data integration
• Individual-level statistical analysis
• Clinician/researcher dashboards
• Patient-facing feedback loops
• Integration with EHR/genomics/lab data

Emerging personalized medicine stacks

For clinical precision medicine rather than classic n-of-1 trials, workflows increasingly combine:

• EHR + genomics + pharmacogenomics
• Wearable/continuous monitoring data
• AI-based clinical decision support
• Patient-specific dosing models
• Adaptive clinical trials

Examples include precision oncology platforms, pharmacogenomics decision-support tools, and AI-guided dosing systems.

If you are evaluating platforms for a research lab, clinical practice, digital therapeutic, or patient self-experimentation, the best options differ substantially.

Platforms supporting N-of-1 therapy designs and personalized medicine workflows span open-source digital health tools, academic-clinical infrastructure, and AI-driven dosage optimization engines.

Open-Source and Academic Digital Platforms

• StudyU Platform : An open-source suite designed for researchers and clinicians to create, publish, and manage digital N-of-1 trials. It includes the StudyU Designer (a collaborative web interface for configuring multi-crossover trial protocols, randomizations, and eligibility criteria) and the StudyU App for participant tracking and metric collection.
• StudyMe : A user-centric, open-source mobile application aimed at non-experts and self-experimenters. Unlike institutional tools built strictly for clinicians, StudyMe allows individuals to build customized single-subject tracking trials with flexible scheduling, variable reminder settings, and symptom measure libraries while storing data locally on-device.
• N-of-1 Hub : A collaborative network and service provider that assists clinicians, academic researchers, and life science companies in designing, running, and analyzing single-case experimental designs (SCED) and personalized crossover trials.

Clinical Workflow and AI Dosing Engines

• CURATE.AI : A pioneering artificial intelligence platform that utilizes a patient’s own longitudinal clinical data (rather than population averages) to dynamically optimize drug dosing and combination therapies over time. It has been deployed in oncology and post-transplant immunosuppressant management.
• Digital Infuzion (N-of-1 Health Research Platform) : An enterprise-grade, real-time architecture integrating electronic health records (EMR) and electronic data capture (EDC) to manage patient-reported outcomes for single-patient registries and observational precision medicine research.
• Trialist App : A targeted mobile health application framework evaluated in academic trials (such as chronic pain management studies) designed to seamlessly guide patients and providers through structured multi-period crossover evaluations.

If you are looking to deploy one of these solutions, tell me:

• Are you building an academic/clinical research study or a self-tracking/consumer workflow?
• Do you need integration with wearables/sensors or Electronic Health Records (EHR)?

I can help narrow down the best technical architecture or open-source path for your project.

Yes. The ecosystem is still fairly fragmented: there are a few platforms built specifically around N-of-1 trials, while most “personalized medicine” platforms handle genomic/clinical data, decision support, or adaptive dosing rather than the full N-of-1 loop.

1. StudyU — probably the closest match

StudyU is explicitly designed for digital N-of-1 trials. Its Designer lets researchers/clinicians specify and conduct N-of-1 studies, while its participant app collects longitudinal data. It is also open source and supports self-hosting.

If your workflow is:

define intervention → randomize/crossover → collect repeated outcomes → analyze within-person effect → generate individualized conclusion

StudyU is the clearest off-the-shelf example I found.

2. CURATE.AI — individualized treatment optimization

CURATE.AI is somewhat different: rather than simply running an N-of-1 trial, it uses repeated dose–response pairs to construct a patient-specific model and update treatment recommendations over successive cycles. The published N-of-1 medicine literature describes both calibration and efficacy-driven phases.

This is particularly interesting for drug dosing, oncology, hypertension, and other settings where treatment intensity can be repeatedly adjusted.

3. PrecisionRx AI — emerging N-of-1 + precision-medicine stack

PrecisionRx AI is unusually close to what you may mean by a broader personalized-medicine workflow platform. It describes a clinician-facing decision-support product that integrates genomic, laboratory, medication, and wearable information, alongside a separate therapeutics studio intended for N-of-1 and ultra-rare-disease work.

I'd classify this as an emerging platform rather than an established clinical-research standard.

4. Medidata — infrastructure rather than an N-of-1 product

Medidata is much more general-purpose. Its platform connects study, patient, and data workflows and is used across large-scale clinical research.

You could build an individualized/adaptive protocol on top of that sort of infrastructure, but you'd likely need substantial configuration/custom analytics. It isn't designed around the distinctive needs of N-of-1 experimentation.

5. Precision-medicine/EHR platforms

There is also an important category that isn't really a commercial “N-of-1 platform”: institutional precision-medicine infrastructure.

For example, UCSF's BRIDGE platform integrates EHR data from Epic with research/other data sources, calculates patient-specific clinical indices, and presents them within the clinician's workflow.

That's a good model if the objective is:

EHR + genomics + biomarkers + wearables → patient-specific model → clinician decision → longitudinal monitoring

rather than a formal randomized N-of-1 experiment.

The key distinction

I'd divide the market into three layers:

A. N-of-1 experimentation

• StudyU
• Custom research platforms
• Emerging “platform-of-1” approaches

B. Individualized treatment optimization

• CURATE.AI
• Other model-based dose optimization systems

C. Precision-medicine clinical workflow

• PrecisionRx AI
• Institutional/EHR-integrated platforms
• Medidata and other clinical-trial infrastructure

And there is an emerging fourth layer: AI + N-of-1. Recent work explicitly proposes using foundation models to generate individualized treatment candidates and then using N-of-1 experiments to establish causal effects in the individual.

If you're evaluating platforms for building an actual N-of-1 therapy program, I'd focus first on StudyU vs. CURATE.AI vs. a configurable EDC/clinical platform, because their underlying philosophies are quite different.

Platforms supporting N-of-1 trial design and personalized medicine workflows generally fall into two categories: open-source digital health ecosystems designed for academic or self-directed trials, and proprietary AI-driven clinical platforms tailored for precision dosing and treatment optimization.

Open-Source and Digital Health Platforms

• StudyU : An open-source digital platform explicitly built for creating, publishing, and conducting digital N-of-1 trials and single-case experimental designs. It features the StudyU Designer (a collaborative web application for scientists/clinicians to specify study protocols) and the StudyU App (a mobile app for participants to follow randomized intervention schedules and track health outcomes).
• StudyMe : A user-centric, open-source mobile application (derived from the same framework as StudyU) intended for non-experts. It guides individual users through configuring their own N-of-1 self-experiments, setting reminder schedules, and tracking personal health goals without needing deep clinical research expertise.
• Stats-of-1 / ICN Resources : Backed by the International Collaborative Network for N-of-1 Trials and Single-Case Designs (ICN), Stats-of-1 acts as a prominent repository providing statistical guidance, design templates, and methodological resources for conducting rigorous N-of-1 research.

AI and Phenotypic Optimization Platforms

• CURATE.AI : Developed at the National University of Singapore (NUS) Institute for Digital Medicine, this is an artificial intelligence platform that uses "small data" exclusively from an individual patient. By mapping longitudinal phenotypic responses (such as daily biomarker levels or cognitive performance scores) against drug dosages, CURATE.AI dynamically generates real-time, forward-looking dose recommendations tailored specifically to that single patient.
• QPOP (Quadratic Phenotypic Optimization Platform) : Another small-data, AI-driven platform used alongside or within precision oncology and hematology workflows. QPOP identifies optimal drug combinations and individualized dosing strategies from a pool of candidates by testing minimal ex-vivo patient samples.

Professional Consultancy Networks

• N-of-1 Hub : While not software per se, the N-of-1 Hub functions as a specialized global service and training provider. They assist clinicians, researchers, and digital health companies in designing bespoke personalized clinical trials, managing N-of-1 workflows, and analyzing single-case data.

If you are planning a specific project, let me know:

• Are you looking for a patient-facing mobile app (like StudyU/StudyMe), or a clinical decision support tool for dosing/oncology?
• Do you need tools for academic research or clinical practice?

I can help narrow down the best technical architecture or statistical approach for your workflow.